Aileron Therapeutics Inc (ALRN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aileron Therapeutics Inc (ALRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7957
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aileron Therapeutics Inc (Aileron Therapeutics) is a biopharmaceutical company that discovers, develops, and commercializes novel class of therapeutics. The company provides products such as stapled peptide drugs. Its stapled peptides penetrate cells throughout the body and modulate intracellular protein-protein interactions. Aileron Therapeutics’ products are used for therapeutic areas of cancer, inflammation, and endocrine and metabolic diseases. The company’s product candidate ALRN-6924 targets the tumor suppressor protein p53 for the treatment of cancers. It also uses peptide stabilization technology. The company partners with research organizations to provides its products. Aileron Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Aileron Therapeutics Inc (ALRN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 10
Aileron Therapeutics Raises US$30 Million In Series E Financing 12
Aileron Raises US$12 Million In Extended Series D Financing 14
Equity Offering 16
Aileron Therapeutics Plans to Raise up to USD150 Million in Public Offering of Securities 16
Aileron Therapeutics Raises USD56.3 Million in IPO 17
Aileron Therapeutics Raises USD19 Million in Private Placement of Shares 19
Aileron Therapeutics Inc – Key Competitors 20
Aileron Therapeutics Inc – Key Employees 21
Aileron Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 07, 2018: Aileron Therapeutics announces second quarter 2018 financial results 23
May 09, 2018: Aileron Therapeutics Reports First Quarter 2018 Financial Results 25
Apr 02, 2018: Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 27
Nov 09, 2017: Aileron Therapeutics Reports Third Quarter 2017 Financial Results 30
Aug 10, 2017: Aileron Therapeutics Reports Second Quarter 2017 Financial Results 32
Corporate Communications 34
Jun 15, 2017: Aileron Therapeutics Appoints Donald Dougherty as Senior Vice President and Chief Financial Officer 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aileron Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 10
Aileron Therapeutics Raises US$30 Million In Series E Financing 12
Aileron Raises US$12 Million In Extended Series D Financing 14
Aileron Therapeutics Plans to Raise up to USD150 Million in Public Offering of Securities 16
Aileron Therapeutics Raises USD56.3 Million in IPO 17
Aileron Therapeutics Raises USD19 Million in Private Placement of Shares 19
Aileron Therapeutics Inc, Key Competitors 20
Aileron Therapeutics Inc, Key Employees 21

List of Figures
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Aileron Therapeutics Inc (ALRN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Accrol Group Holdings PLC (ACRL):企業の財務・戦略的SWOT分析
    Accrol Group Holdings PLC (ACRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Toleranzia AB-製薬・医療分野:企業M&A・提携分析
    Summary Toleranzia AB (Toleranzia) is a developer of platform technology for the treatment of autoimmune diseases. The company develops and offers products and technologies including Re-Tolerogen for the treatment of autoimmune diseases. Its Re-Tolerogen platform technology is a fusion protein for t …
  • KeyCorp:企業の戦略・SWOT・財務情報
    KeyCorp - Strategy, SWOT and Corporate Finance Report Summary KeyCorp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Ernst & Young Global Ltd
    Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report Summary Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Companhia Energetica de Minas Gerais SA:発電所・企業SWOT分析
    Companhia Energetica de Minas Gerais SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informat …
  • Beth Israel Deaconess Medical Center Inc-製薬・医療分野:企業M&A・提携分析
    Summary Beth Israel Deaconess Medical Center Inc (BIDMC), a subsidiary of CareGroup Inc is a healthcare center that offers clinical care, biomedical research and education, health and wellness services. The center offers patient and family care services such as admitting, case management, ethics sup …
  • OSX Brasil SA (OSXB3):石油・ガス:M&Aディール及び事業提携情報
    Summary OSX Brasil SA (OSX), formerly EBX Brasil SA is an oil and gas company. The company provides equipment and services to operate in the naval and offshore industry. It offers integrated engineering, construction, chartering, and operation and maintenance services for oil exploration and product …
  • CaixaBank SA:戦略・SWOT・企業財務分析
    CaixaBank SA - Strategy, SWOT and Corporate Finance Report Summary CaixaBank SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Bailian Group Co., Ltd.:企業の戦略的SWOT分析
    Bailian Group Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Sun Hydraulics Corporation:企業の戦略・SWOT・財務情報
    Sun Hydraulics Corporation - Strategy, SWOT and Corporate Finance Report Summary Sun Hydraulics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Patrys Ltd (PAB):製薬・医療:M&Aディール及び事業提携情報
    Summary Patrys Ltd (Patrys) is a therapeutic antibody development company focused on IgM antibodies and IgG antibody fragments in the field of oncology. The company's pipeline products include PAT-SC1 an immunoglobulin M (IgM) type antibody used for the treatment of gastric cancer; PAT-SM6 is a full …
  • Harsco Corp:企業の戦略・SWOT・財務情報
    Harsco Corp - Strategy, SWOT and Corporate Finance Report Summary Harsco Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Eiffage SA (FGR):電力:M&Aディール及び事業提携情報
    Summary Eiffage SA (Eiffage) is a construction and concession company. It operates in businesses of energy and infrastructure construction, real estate development, road construction, civil engineering, concessions, and public-private partnerships. The company’s activities include construction, reno …
  • Arise AB (ARISE)-エネルギー分野:企業M&A・提携分析
    Summary Arise AB (Arise) is an independent onshore wind company. It has a presence in the entire value chain from prospecting and permit management to financing, construction, sale, and long-term management of its own and others’ wind farms. The company owns wind plants in southern Sweden; and co-ow …
  • Ecclesiastical Insurance Group plc:企業の戦略・SWOT・財務情報
    Ecclesiastical Insurance Group plc - Strategy, SWOT and Corporate Finance Report Summary Ecclesiastical Insurance Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • RainDance Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary RainDance Technologies Inc (RDT), a subsidiary of Bio-Rad Laboratories Inc is a developer of genomic tools for non-invasive liquid biopsy applications. The company’s products include RainDrop Plus, a digital PCR system that provides picoliter droplets for multiplex detection of HIV and DNA; …
  • Metgasco Ltd (MEL):石油・ガス:M&Aディール及び事業提携情報
    Summary Metgasco Ltd (Metgasco) is an oil and gas exploration company. The company that acquires, explores, produces, and develops oil and gas, petroleum and hydrocarbon assets. It holds interests in Clarence Moreton Basin, an exploration license located in northern New South Wales. Metgasco supplie …
  • Total SA (FP):石油・ガス:M&Aディール及び事業提携情報
    Summary Total SA (Total) is an integrated global energy company that discovers, produces, refines and markets oil and gas, and also manufactures petrochemicals. It carries out drilling, oil and gas production, processing, transportation, refining and petrochemical production, storage and distributio …
  • Cepheid:医療機器:M&Aディール及び事業提携情報
    Summary Cepheid, a subsidiary of Danaher Corporation, is a molecular diagnostic company that develops, manufactures and markets molecular systems and tests for clinical and non-clinical markets. The company offers in vitro diagnostic tests for health care associated infections, critical infectious d …
  • Compania Espanola de Petroleos SAU:企業の戦略的SWOT分析
    Compania Espanola de Petroleos SAU - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆